HNRNPA2B1 and cancer: Our results show that these small molecules with high affinity to HNRNPA2B1 can play a role in endocrine resistance therapy of cancer by targeting HNRNPA2B1, but the specific mechanism and application value still need further mechanism exploration and clinical trials.